AGIO
NASDAQAgios Pharmaceuticals Inc.
Price$33.88+0.47 (+1.41%)
01:30 PM07:45 PM
News · 26 weeks63-67%
2026-03-012026-08-23
Mix3390d
- Insider20(61%)
- Other5(15%)
- Earnings4(12%)
- SEC Filings4(12%)
Latest news
25 items- INSIDERChief Medical Officer Gheuens Sarah sold $914,400 worth of shares (30,000 units at $30.48) as part of a pre-agreed trading plan, decreasing direct ownership by 35% to 54,645 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Agios Pharmaceuticals Inc.SCHEDULE 13G/A - AGIOS PHARMACEUTICALS, INC. (0001439222) (Subject)
- SECSEC Form 10-Q filed by Agios Pharmaceuticals Inc.10-Q - AGIOS PHARMACEUTICALS, INC. (0001439222) (Filer)
- SECAgios Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - AGIOS PHARMACEUTICALS, INC. (0001439222) (Filer)
- PRAgios Reports Second Quarter 2026 Financial Results and Provides Business UpdateMitapivat (PYRUKYND® and AQVESME™) delivered worldwide net revenues of $44.7 million in the second quarter of 2026, compared to $12.5 million in the second quarter of 2025Strong U.S. commercial launch of AQVESME in thalassemia, with 442 cumulative prescriptions written as of June 30, 2026sNDA for mitapivat granted FDA Priority Review in sickle cell disease with PDUFA goal date of November 1, 2026Diversified and expanded late-stage pipeline with licensing of cevidoplenib for immune thrombocytopenia and advancement of AG-236 into Phase 2/3 development for polycythemia vera $964.8 million in cash, cash equivalents, and marketable securities as of June 30, 2026; well capitalized to support comme
- PRAgios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell DiseaseHemoglobin response rates for tebapivat, a PK activator, were consistent with the class of medicine, but Phase 2 results did not establish a differentiated profile to support continued development in sickle cell diseaseSafety and tolerability of tebapivat were consistent with prior sickle cell disease trialssNDA for mitapivat, company’s foundational PK activator, is under FDA Priority Review in sickle cell disease; PDUFA goal date is November 1, 2026 CAMBRIDGE, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced topline re
- INSIDERDirector Backstrom Jay T. was granted 1,447 shares (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- PRU.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell DiseaseFDA’s PDUFA goal date is November 1, 2026If approved, mitapivat is positioned to become the first oral PK activator for patients with sickle cell disease CAMBRIDGE, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for mitapivat, an oral pyruvate kinase (PK) activator, in sickle cell disease with a Priority Review. The Prescription Drug User Fee Act (PDUFA) goal date for this sNDA, submitted under the FDA’s accelera
- SECSEC Form SCHEDULE 13G filed by Agios Pharmaceuticals Inc.SCHEDULE 13G - AGIOS PHARMACEUTICALS, INC. (0001439222) (Subject)
- INSIDERChief Medical Officer Gheuens Sarah sold $150,503 worth of shares (4,007 units at $37.56) as part of a pre-agreed trading plan and converted options into 8,375 shares, increasing direct ownership by 5% to 84,645 units (SEC Form 4) to cover withholding tax4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- PRAgios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 a.m. ETCAMBRIDGE, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced the company will host a conference call and live webcast on Thursday, July 30, 2026, at 8:00 a.m. ET to report its second quarter 2026 financial results and business highlights. The live webcast will be accessible on the Investors section of the company’s website (www.agios.com) under the "Events & Presentations" tab. A replay of the webcast will be available on the company’s website approximately two hours after the event. About Agios: Fueled by Connections t
- INSIDERDirector Ballal Rahul D. converted options into 2,816 shares, increasing direct ownership by 23% to 15,230 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- INSIDERDirector Capello Jeffrey D converted options into 2,816 shares, increasing direct ownership by 35% to 10,865 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- INSIDERDirector Foster-Cheek Kaye I converted options into 2,816 shares, increasing direct ownership by 38% to 10,284 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- INSIDERDirector Fouse Jacqualyn A converted options into 2,816 shares, increasing direct ownership by 2% to 154,156 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- INSIDERDirector Ho Maykin converted options into 2,816 shares, increasing direct ownership by 17% to 19,848 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- INSIDERDirector Owen Adams Catherine converted options into 2,816 shares, increasing direct ownership by 35% to 10,865 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- INSIDERDirector Scadden David converted options into 2,816 shares, increasing direct ownership by 16% to 20,419 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- INSIDERDirector Smith Cynthia converted options into 2,816 shares, increasing direct ownership by 23% to 15,230 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- INSIDERSEC Form 4 filed by Chief Strategy and Operations Viswanadhan Krishnan4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Goff Brian4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- INSIDERSEC Form 4 filed by Chief Legal Officer Burns James William4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- INSIDERSEC Form 4 filed by Chief Medical Officer Gheuens Sarah4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Jones Cecilia4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- INSIDERSEC Form 4 filed by Chief Commercial Officer Milanova Tsveta4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
AGIO FAQ
7 questionsWhat does Agios Pharmaceuticals Inc. do?
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA (enasidenib), an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat...Where does AGIO stock trade?
Agios Pharmaceuticals Inc. (AGIO) is listed on NASDAQ.What sector and industry is AGIO in?
Agios Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Agios Pharmaceuticals Inc. go public?
Agios Pharmaceuticals Inc. (AGIO) completed its IPO in 2013.What are analysts saying about AGIO?
Agios Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy on 2026-04-20. Recent price targets range from $2800.00 to $3400.00.What companies are similar to AGIO?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare AGIO side-by-side with any of them on Quantisnow.How can I track AGIO on Quantisnow?
Quantisnow aggregates Agios Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AGIO to receive live email and push alerts on every new disclosure.